Higher Serum PD-L1 Level May Be Predictive Factor For Better Response To Lapatinib Than Trastuzumab In Patients With HER2-Positive Metastatic Breast Cancer, Study Indicates

Cancer Network (10/18, Slater) reports researchers found in the retrospective phase 3 Canadian Cancer Trials Group MA.31 trial that “a higher serum PD-L1 level was a significant predictive factor for a better response to lapatinib (Tykerb) than trastuzuma...